STOCK TITAN
  1. Home
  2. News
  3. AZN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

News
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
Rhea-AI Summary
AstraZeneca's TRUQAP (capivasertib) Approved in the US for HR-positive, HER2-negative breast cancer with specific biomarker alterations, showing a 50% reduction in the risk of disease progression or death. The approval is based on the CAPItello-291 Phase III trial results, offering a new treatment option for patients with these specific biomarkers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
News
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
Rhea-AI Summary
AstraZeneca: Positive results from the EMERALD-1 Phase III trial show that IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated significant improvement in progression-free survival versus TACE alone in patients with hepatocellular carcinoma. The trial continues to follow the secondary endpoint of overall survival. The safety profiles for IMFINZI and TACE plus bevacizumab were consistent with the known profile of each medicine, and there were no new safety findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
clinical trial
-
News
AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
Rhea-AI Summary
AstraZeneca (AZN) aims to significantly increase US renewable natural gas (RNG) productivity through an expanded collaboration with Vanguard Renewables. The partnership seeks to accelerate parity with fossil fuel-generated natural gas by leveraging AstraZeneca's global industrial-scale manufacturing and digital capabilities. The collaboration plans to increase RNG yield and generate a step change improvement in production, aiming to enhance access and cost-effectiveness of RNG. The announcement builds on a prior sector-first collaboration and contributes to AstraZeneca's Ambition Zero Carbon strategy for value chain decarbonization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News
Compugen Reports Third Quarter 2023 Results
Rhea-AI Summary
Compugen Ltd. announced the progress of rilvegostomig, AstraZeneca's PD-1/TIGIT bi-specific derived from Compugen's COM902, into Phase 3 as adjuvant therapy for biliary tract cancer. Enrollment was completed in a proof-of-concept study for metastatic colorectal cancer. The company presented new clinical data at SITC 2023, reinforcing the anti-tumor activity of COM701 and initial data suggesting PVRL2 as a potential biomarker. Pre-clinical data also highlighted the potential of COM503's antibody approach to treat cancer. Financial results showed cash, cash equivalents, and cash investments of approximately $57.5 million as of September 30, 2023, expected to fund operations through the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
earnings
-
News
Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
Rhea-AI Summary
AstraZeneca announces positive results from the Phase IIb ZENITH-CKD trial, showing significant reductions in urinary albumin-to-creatinine ratio (UACR) with the combination of zibotentan and dapagliflozin compared to dapagliflozin alone. The high-dose combination resulted in a 52.5% reduction, while the low-dose combination showed a 47.7% reduction. The trial also demonstrated acceptable tolerability with low rates of fluid retention. Plans for Phase III are underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
clinical trial
-
News
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
Rhea-AI Summary
AstraZeneca's Supplemental Biologics License Application for a self-administered flu vaccine has been accepted for review by the FDA. If approved, FLUMIST QUADRIVALENT will be the first flu vaccine that can be self-administered or administered by caregivers. The FDA's decision is expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
News
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Rhea-AI Summary
Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2 expressing advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
-
News
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU shows positive results in the primary analysis of the DESTINY-PanTumor02 Phase II trial, demonstrating clinically meaningful responses and a survival benefit in previously treated patients with HER2-expressing solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
-
News
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Rhea-AI Summary
Positive results from the pivotal TROPION-Lung01 phase 3 trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
News
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan shows positive results in Phase III trial for breast cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
Stock AZN logo
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

#37 Ranked by Market Cap
#1673 Ranked by Stock Gains
#1172 Ranked by Dividends

AZN Stock Data

212.97B
1.54B
0.01%
16.8%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.